Novel agents and immune invasion in Hodgkin lymphoma

The approval of brentuximab vedotin (BV) and the PD-1 inhibitors nivolumab and pembrolizumab has dramatically improved outcomes for patients with relapsed or refractory (R/R) classic Hodgkin lymphoma (HL). With the goal of increasing long-term disease control rates and decreasing late toxicities, th...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Hematology Am Soc Hematol Educ Program
Main Authors: Merryman, Reid W., LaCasce, Ann
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2019
Fag:
Hodgkin Lymphoma: Celebrating 200 Years since Thomas Hodgkin Entered Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913426/
https://ncbi.nlm.nih.gov/pubmed/31808827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000029
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker